PURPLE BIOTECH LTD.: INTRACOASTAL CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Intracoastal Capital, LLC amended its Schedule 13G stake filing for Purple Biotech Ltd., disclosing the change to the SEC under accession number 0001213900-26-118162. The filing updates the investor's previously reported position in the biotech company, though the amended document did not specify a revised share count or percentage in the headline disclosure. Schedule 13G amendments are typically watched for signals of shifting institutional ownership, particularly in small-cap biotech names where concentrated holders can influence governance and trading liquidity. Investors will look to the full filing for the exact size and direction of Intracoastal's position change.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Purple Biotech Ltd., Intracoastal Capital, LLC